Prostate cancer:
Facts and scientific update for the EU Cancer Plan

Elevated PSA*
50-59: ≥3.0 (1000/10,000)
60-70: ≥3.0 (2500/10,000)

Reflex testing**
High and intermediate Risk (65%)

mpMRI**
(100%)

PIRADS 1-2
(54%)

PIRADS 3
(6%)

PIRADS 4-5
(40%)

Low risk
(35% MRI avoided)

PSA <0.15
Low risk (57%)
(no biopsy)

PSAD >0.15
Intermediate and high risk (43%)

Target +/- Systematic biopsy

Clinical follow-up

No cancer
(8%)

PCa
(35%)

* Once confirmed with 2-4 weeks interval.
** Eventually replaced by tri- or bi-parametric MRI.
*** Family history, African-American origin, PSA density, BRCA2 gene mutation, nomograms/risk calculator (ERSPC and PCPT).

Low and intermediate Risk (65%)

Active surveillance
Grade Group 1 = 25%
Grade Group >1 = 75%
Active treatment

PSAD <0.15
Low risk
(57%)

(35% MRI avoided)

High and intermediate
(43%)

Intermediate and high risk
(43%)

Target +/- Systematic biopsy

Clinical follow-up

No cancer
(8%)

PCa
(35%)